Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO) - Full Text View

Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse.

(CALYPSO)

This study is ongoing, but not recruiting participants.

First Received: October 1, 2007 No Changes Posted

Sponsored by:	King Faisal Specialist Hospital & Research Center
Information provided by:	King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier:	NCT00538603

Purpose

Multi-national, randomized, phase III, GCIG Intergroup study comparing pegylated liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in patients with epithelial ovarian cancer in late relapse.

(CALYPSO)

Condition	Intervention
Epithelial Ovarian Cancer	Drug: pegylated liposomal Doxorubicin (CAELYX) & Carboplatin Drug: Paclitaxel & Carboplatin

Study Type:	Interventional
Study Design:	Open Label, Single Group Assignment

Resource links provided by NLM:

MedlinePlus related topics: Cancer Ovarian Cancer

Drug Information available for: Doxorubicin Doxorubicin hydrochloride Paclitaxel Carboplatin Myocet

U.S. FDA Resources

Eligibility

Genders Eligible for Study:

Both

Criteria

Inclusion Criteria:

Patients with epithelial Ovarian cancer in late relapse

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00538603

Sponsors and Collaborators

King Faisal Specialist Hospital & Research Center

Investigators

Principal Investigator:

Adnan Munkarah, MD

King Faisal Specialist Hospital & Research Centre

More Information

No publications provided

Study ID Numbers:	RAC #2051-062
Study First Received:	October 1, 2007
Last Updated:	October 1, 2007
ClinicalTrials.gov Identifier:	NCT00538603 History of Changes
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Ovarian Neoplasms
Gonadal Disorders
Genital Neoplasms, Female
Endocrine System Diseases
Urogenital Neoplasms
Antimitotic Agents
Carboplatin
Ovarian Diseases
Ovarian Epithelial Cancer

Doxorubicin
Genital Diseases, Female
Anti-Bacterial Agents
Paclitaxel
Tubulin Modulators
Ovarian Cancer
Endocrinopathy
Antineoplastic Agents, Phytogenic
Endocrine Gland Neoplasms

Additional relevant MeSH terms:

Ovarian Neoplasms
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Gonadal Disorders
Mitosis Modulators
Genital Neoplasms, Female
Endocrine System Diseases
Urogenital Neoplasms
Antimitotic Agents
Ovarian Diseases
Carboplatin
Antibiotics, Antineoplastic

Pharmacologic Actions
Doxorubicin
Adnexal Diseases
Genital Diseases, Female
Neoplasms
Neoplasms by Site
Paclitaxel
Therapeutic Uses
Tubulin Modulators
Antineoplastic Agents, Phytogenic
Endocrine Gland Neoplasms

ClinicalTrials.gov processed this record on September 11, 2009